Terms: = Prostate cancer AND PCSK7, Q16549, 9159, ENSG00000160613, PC8, SPC7, PC7, LPC AND Prognosis
7 results:
1. Combining PHI and miRNAs as Biomarkers in prostate cancer Diagnosis and prognosis.
Ibrahim NH; Abdellateif MS; Thabet G; Kassem SH; El-Salam MA; El-Leithy AA; Selim MM
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307177
[TBL] [Abstract] [Full Text] [Related]
2. An Analytical Study of prostate-Specific Antigen Dynamics.
Esteban EP; Deliz G; Rivera-Rodriguez J; Laureano SM
Comput Math Methods Med; 2016; 2016():3929163. PubMed ID: 27956935
[TBL] [Abstract] [Full Text] [Related]
3. Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and prognosis in prostate cancer: A Systematic Review and Meta-Analysis.
Cao J; Zhu X; Zhao X; Li XF; Xu R
PLoS One; 2016; 11(7):e0158770. PubMed ID: 27368058
[TBL] [Abstract] [Full Text] [Related]
4. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.
Goto T; Terada N; Inoue T; Kobayashi T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Utsunomiya N; Makino Y; Sumiyoshi S; Yamasaki T; Kamba T; Ogawa O
Prostate; 2015 Dec; 75(16):1821-30. PubMed ID: 26332786
[TBL] [Abstract] [Full Text] [Related]
5. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation.
Resel Folkersma L; Olivier Gómez C; San José Manso L; Veganzones de Castro S; Galante Romo I; Vidaurreta Lázaro M; de la Orden GV; Arroyo Fernández M; Díaz Rubio E; Silmi Moyano A; Maestro de Las Casas MA
Arch Esp Urol; 2010; 63(1):23-31. PubMed ID: 20157216
[TBL] [Abstract] [Full Text] [Related]
6. Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer.
Beydoun HA; Mohan R; Beydoun MA; Davis J; Lance R; Schellhammer P
BJU Int; 2010 Aug; 106(3):334-41. PubMed ID: 20151969
[TBL] [Abstract] [Full Text] [Related]
7. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining.
Fromont G; Vallancien G; Validire P; Levillain P; Cussenot O
Prostate; 2007 Feb; 67(3):268-73. PubMed ID: 17192874
[TBL] [Abstract] [Full Text] [Related]
